I'm LongbridgeAI, I can summarize articles.The Week
Moderna fell 12.12% this week to $223.37, while the S&P 500 gained 2.51%, leaving the stock roughly 14.63 percentage points behind the index. The move was a fade from highs: Monday’s session touched a weekly high of $280.80, and the following four sessions slid lower, closing near the lower end of the $221.70–$231.35 range on Friday. Weekly amplitude came to 22.92%, with 46.2m shares traded. Average daily volume of about 9.24m shares ran roughly 43% below the 60-session median, so turnover was relatively light.
Key Events
Company news flowed thick this week. Gains built early, with Moderna up more than 8% intraday on Monday and hitting a 52-week high; Tuesday’s post-market results showed a surprise profit that confounded analyst expectations. Ratings and pipeline data then took over: Piper Sandler maintained Overweight and raised its target to $305, while Goldman Sachs stayed Neutral and lifted its target to $195. On Thursday the company raised its 2026 revenue growth outlook to 15%–25% from up to 10%, highlighted positive intismeran data, extended its $1.5bn Ares credit facility maturity to 2031, and guided 2027 cash costs of around $4bn. MSCI also announced on Thursday that Moderna would be added to its global index. Price action turned lower from Wednesday, with put options seeing active trading.
Analyst Ratings
Among the 23 institutions covering Moderna this week, 3 rate it buy, 1 overweight, 16 hold, 1 underweight and 2 sell. The consensus rating is hold, and the consensus target of $158.47 sits about 29.05% below the spot. Targets are wide apart, ranging from $305 at the top to $45 at the bottom. Within biotechnology, Moderna ranks 19th out of 514 rated names, versus an industry mean of 8 and a median of 6.
The Week Ahead
US macro data dominates the coming days: the New York Fed manufacturing index arrives on Monday, 16 November, with a prior print of 25.5 and a 18 forecast; Tuesday, 17 November brings retail sales, retail sales excluding autos, import prices, industrial production and the NAHB housing market index. On the company side, Moderna reports fiscal 2026 annual results on Thursday, 11 February 2027, giving the first chance to test the raised revenue guidance against actual performance. This week’s intismeran data and personalised cancer vaccine updates may also get fuller reads at upcoming medical conferences.
In Short
The tension this week is between warming fundamentals and a cooling tape. The company posted a surprise profit, raised its 2026 growth outlook, showed positive intismeran data and won inclusion in the MSCI World Index, while the valuation sits near 13x PB and negative PE. Yet the stock faded from highs, large-lot money turned net seller in the latest session, and the consensus target sits almost a third below spot with wide disagreement. What to watch: whether the raised guidance holds up at the next report, and whether oncology pipeline progress narrows the gap between the $305 and $45 targets.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
